October 2021 OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum
October 2021 OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference
October 2021 OSE Immunotherapeutics Announces that the IDMC Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi®
October 2021 OSE Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma